1 Large-Scale Validation Study of an Improved Semi-Autonomous Urine Cytology

- 2 Assessment Tool: AutoParis-X
- 3 Joshua J. Levy PhD^{1,2,3,4,*}, Natt Chan MS⁴, Jonathan D. Marotti MD^{1,6}, Darcy A. Kerr MD^{1,6},
- 4 Edward J. Gutmann MD, AM^{1,6}, Ryan E. Glass MD⁵, Caroline P. Dodge⁷, Arief A. Suriawinata
- 5 MD^{1,6}, Brock Christensen PhD^{3,8,9}, Xiaoying Liu MD^{1,6,†}, Louis J. Vaickus MD, PhD^{1,6,†}
 - 1. Emerging Diagnostic and Investigative Technologies, Department of Pathology and
 - Laboratory Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, 03766
 - 2. Department of Dermatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, 03766
- 9 3. Department of Epidemiology, Dartmouth College Geisel School of Medicine, Hanover,
 10 NH, 03756
- Program in Quantitative Biomedical Sciences, Dartmouth College Geisel School of Medicine, Hanover, NH, 03756
 - 5. UPMC East, Pittsburg, PA, 15146
 - 6. Dartmouth College Geisel School of Medicine, Hanover, NH, 03756
- 15 7. Cambridge Health Alliance, Cambridge, MA, 02139
- Bepartment of Molecular and Systems Biology, Dartmouth College Geisel School of Medicine, Hanover, NH, 03756
- Department of Community and Family Medicine, Dartmouth College Geisel School of Medicine, Hanover, NH, 03756
- * To whom correspondence should be addressed: joshua.j.levy@dartmouth.edu
- 22 † Authors contributed equally
- 23

20

6

7

8

13

14

24 Author Contributions

- 25 JL and LV: conceptualization, formal analysis, funding acquisition, investigation, methodology,
- 26 project administration, resources, software, supervision, validation, visualization, writing -
- original draft; XL, JM, DK, EG, RG, CD, LV: data curation; all authors: writing review and
- 28 editing
- 29

30 **Conflict of Interest**

- 31 None to disclose.
- 32
- 33

34 Abstract

- 35 Adopting a computational approach for the assessment of urine cytology specimens has the
- 36 potential to improve the efficiency, accuracy and reliability of bladder cancer screening, which
- 37 has heretofore relied on semi-subjective manual assessment methods. As rigorous, quantitative
- 38 criteria and guidelines have been introduced for improving screening practices, e.g., The Paris
- 39 System for Reporting Urinary Cytology (TPS), algorithms to emulate semi-autonomous
- 40 diagnostic decision-making have lagged behind, in part due to the complex and nuanced nature
- 41 of urine cytology reporting. In this study, we report on a deep learning tool, AutoParis-X, which
- 42 can facilitate rapid semi-autonomous examination of urine cytology specimens. Through a large-
- 43 scale retrospective validation study, results indicate that AutoParis-X can accurately determine
- 44 urothelial cell atypia and aggregate a wide-variety of cell and cluster-related information across a
- 45 slide to yield an Atypia Burden Score (ABS) that correlates closely with overall specimen atypia,
- 46 predictive of TPS diagnostic categories. Importantly, this approach accounts for challenges
- 47 associated with assessment of overlapping cell cluster borders, which improved the ability to
- 48 predict specimen atypia and accurately estimate the nuclear-to-cytoplasm (NC) ratio for cells in
- 49 these clusters. We developed an interactive web application that is publicly available and open-
- 50 source, which features a simple, easy-to-use display for examining urine cytology whole-slide
- 51 images (WSI) and determining the atypia level of specific cells, flagging the most abnormal cells
- 52 for pathologist review. The accuracy of AutoParis-X (and other semi-automated digital
- 53 pathology systems) indicates that these technologies are approaching clinical readiness and
- 54 necessitates full evaluation of these algorithms via head-to-head clinical trials.
- 55

57 Introduction

58 Urothelial carcinoma is highly prevalent (9th most common worldwide) and has the highest 59 recurrence rate among all forms of cancer (74%)^{1,2}. The treatment and management of urothelial 60 carcinoma requires follow-up urine cytology (UC), expensive, painful chemotherapy, and/or 61 invasive cystoscopy procedures for long periods of time (typically the remainder of the patient's 62 life), necessitating the development and implementation of less invasive screening and follow up 63 measures ³.

64

65 The detection and screening for bladder cancer has greatly improved since the earliest recorded 66 evaluation of hematuria was recorded in the papyrus of Kahun, circa 1900 B.C.. In 1550 B.C., it was suggested that hematuria originated from "worms in the belly"⁴. A causative agent, S. 67 68 haematobium, was identified in 1854 by Theodor Bilharz ^{5,6}. In 1947, Dr. George Papanicolaou, 69 widely considered the father of modern cytopathology, proposed a formal system for evaluation 70 of malignant cells exfoliated from the bladder's epithelium, which has largely remained intact ^{7,8}. 71 Over the past half-century, efforts to rigorously define quantitative assessment criteria (e.g., 72 nuclear-to-cytoplasm (NC) ratio, chromatin structure, etc.) and improve specimen preparation 73 methods have sought to resolve remaining ambiguity. Yet, traditional cytological approaches are 74 still hampered by inter-rater variability, specimen quality issues, and the tendency towards 'hedging' to the atypical category 9-12. 75

76

77 In recent years, The Paris System for Reporting Urinary Cytology (TPS), formulated in 2013,

published in 2016, and updated in 2022, has emerged as a more quantitative and reproducible

reporting system bladder cancer ^{13–17}. TPS criteria are applied to assign one of four main ordered

80	categories (negative, atypical urothelial cells, suspicious for high-grade urothelial carcinoma,
81	positive for high-grade urothelial carcinoma) based on the following criteria for a positive
82	diagnosis: (1) at least five malignant urothelial cells (updated to ten in 2022), (2) an NC ratio at
83	or above 0.7, (3) nuclear hyperchromasia, (4) markedly irregular nuclear membrane, and (5)
84	coarse/clumped chromatin ² . It is often easier to evaluate specimens that have clear-cut
85	diagnoses, either negative or positive, than those that are atypical or suspicious. Atypical
86	specimens are those that are hedged against a negative diagnosis, while suspicious specimens are
87	those that are hedged against a positive diagnosis, but allow fewer than five malignant cells to be
88	detected. Unsurprisingly, the two indeterminate designations suffer from poor inter-rater
89	variability ^{12,17} .
90	
91	There are a number of drawbacks to cytological assessments, despite improvements in screening
92	criteria: cytology slides are far less structured than traditional histological specimens (as they are
93	a random dispersion of cells); there is high inter-rater variability; and the workload involved
94	often leads to cytologist exhaustion- all of these factors increase the likelihood of
95	misclassification. Furthermore, TPS does not introduce rigorous screening criteria for urothelial
96	cell clusters, instead mainly relying on aggregates of individual cellular estimates. Systems to
97	automate the assessment of cytology specimens can provide more quantitative assessments of
98	atypia, while improving reliability and reproducibility.
99	
100	Advances in cytopathology vis-à-vis increased automation can bring several benefits to all
101	stakeholders in the healthcare space ^{18–22} . The adoption of computer assisted Papanicolaou

102 ('Pap') test screening helped laboratories address overwhelming numbers of tests that formerly

103 required manual screening, leading to inevitable workflow backlogs and diagnostic errors 104 resulting from overwork. The end result of this practice was the drafting of the CLIA-88 105 regulations concerning cytotechnologist workload limits and the development of semi-automated 106 Pap screening devices such as the FocalPoint[™] GS and the ThinPrep [®] Imaging System (TIS) 107 ^{23,24}. The commercial success of these automated systems in the gynecologic cytology market 108 provides a window into the possibilities of future computational applications in urine cytology 109 $^{25-33}$. The factors which drove the creation of automated gynecologic cytology systems are 110 similarly present in urine cytology: to improve clinical outcomes and integrate smoothly within 111 the daily workflows of cytopathology laboratories. Outside of gynecologic cytology, several 112 computational methods have been developed for cytological applications in screening cancers of varying types of specimens ^{18,34–36}. For instance, efforts have been made to screen potential 113 114 malignancies in thyroid fine-needle aspirations (FNA), liquid-based lung cancer specimens, pancreaticobiliary FNA, breast lesions, and urine specimens ³⁷⁻⁴². 115

116

117 Systems to automate cytology screening can provide more quantitative assessments of atypia 118 while improving reliability, precision and reproducibility of findings. State-of-the-art approaches 119 leverage deep learning, which relies on the use of artificial neural networks (ANN- inspired by 120 the central nervous system), to construct indicators of atypia that can be formulated into 121 diagnostic tests. For instance, Sanghvi et al. developed a semi-autonomous diagnostic decision 122 aid for bladder cancer using a deep learning algorithm to quantify abnormal cytomorphological 123 features ⁴³. The algorithm detected urothelial cells using QuPath, urothelial clusters using 124 density-based clustering and used convolutional neural networks for scoring cells for atypia (e.g., 125 NC ratio, hyperchromasia, etc.). Although the effectiveness of QuPath, the scoring algorithms,

and density-based clustering was not fully discussed, the study showed promising results in
estimating overall atypia and could potentially improve bladder cancer screening. However, it
should be noted that other studies have highlighted the limitations of QuPath in disaggregation of
cells within clusters in favor of detection-based approaches, indicating a need for further
refinement of the algorithm ⁴⁴⁻⁴⁷.

131

132 We previously developed the AutoParis system to automatically report the presence of malignant 133 cells across cytology specimens through cross-tabulation of the degree of atypia and NC ratio for all urothelial cells in the preparation ⁴⁸. Cross-tabulation is used to generate an Atypia Burden 134 135 Score (ABS) to directly classify the specimen. The current AutoParis system operates by: 1) 136 using connected component analysis (morphometry) and watershedding to separate individual 137 cells from cell clusters within the specimen; 2) estimating the NC ratio of the cell using a 138 segmentation neural network to separate the nucleus and cytoplasmic components on a pixel-by-139 pixel basis; 3) simultaneously assigning the cell as urothelial and recording whether the cell is 140 atypical (atypia score) from a classifier which separates negative urothelial cells, positive 141 urothelial cells, leukocytes, red blood cells (RBCs), debris, squamous, and crystals; and 4) 142 generating digital images in which the cells are arranged in order of atypia, which could be 143 helpful to pathologists. Limitations in current classification systems for urine cytology include ²⁰: 144 1) confounding by the presence of blood, high cellularity, neobladders (abundant degenerated 145 enterocytes) and scanning artifacts. Other previously unaccounted for cell types may also 146 confound classifiers (e.g., polyomavirus encrusted cells conflated with positive urothelial cells, 147 leukocytes vs. clusters of leukocytes, urothelial cells with no nucleus present, renal tubule cells) 148 ⁴⁹; 2) morphometry algorithms may not scale to hundreds of thousands of cells at maximal

resolution; 3) density-based clustering / watershedding is likely insufficient to separate
overlapping cells; 4) using a single classifier does not adequately separate the tasks of
determining whether a cell is both urothelial and atypical; 6) orientation and size of cell could
confound the classifier; and 7) existing graphical displays for communicating the burden of
atypia are static rather than dynamic.

154

155 We set out to improve on the AutoParis classification tool by addressing the above limitations 156 and additionally trained the models using a more expansive dataset- we dub the new tool 157 AutoParis-X (AP-X). In AutoParis-X, we addressed challenges associated with cell cluster 158 assessment by developing an artificial intelligence tool that uses detection models to localize 159 urothelial cells, overlapping cell boundaries, dense regions of significant overlap, and identify 160 visual markers of urothelial atypia. By breaking clusters into their constituent architectural 161 components, this preprocessing tool facilitates downstream association studies and predictive 162 algorithms that incorporate quantitative cluster-level features. The cell border identification tool 163 helped develop a more comprehensive understanding of urothelial cell cluster atypia as it 164 pertains to bladder cancer screening. In comparison to the previous AutoParis study, which was 165 validated on a small well-curated test set, we performed a large-scale retrospective validation of 166 AutoParis-X on nearly 1,300 real-world specimens from internal cohorts. In this manuscript, we 167 discuss improvements to the previous approach and its potential for real-time assessment as a 168 mature diagnostic decision aid.







182

183 Methods

184 Specimen Collection and Slide Processing

185 A total of 1,303 urine specimens were collected across 140 bladder cancer patients (median of 8

- 186 specimens per patient; IQR: [8-13]) from 2008 to 2019 at Dartmouth-Hitchcock Medical Center.
- 187 Forty-seven of these specimens were used to curate data for training the cell and cluster-level
- 188 machine learning models (*cell and cluster-level training and validation cohort*). Four specimens
- 189 were removed due to equivocal findings and/or excessive confluent cellularity. AutoParis-X was

190	further trained and validated on 1,252 specimens after curating slide-level cell/cluster predictors
191	(slide-level training and validation cohorts; see Calculation of Cell and Cluster Slide-Level
192	Scores). The specimens were prepared using ThinPrep® and Papanicolaou staining before being
193	examined microscopically ²⁴ . The urine slides were scanned using a Leica Aperio-AT2 scanner
194	at $40 \times$ resolution and were stored as 70% quality SVS files representing whole slide images. The
195	slides were manually focused (by a trained technician) on a single plane during scanning, and z-
196	stacking was not used. Patient and slide-level characteristics from the slide-level training and
197	validation cohorts can be found in Table 1. All slides were assessed by a group of five
198	cytopathologists using TPS criteria (negative for high grade urothelial carcinoma, atypical
199	urothelial cells, suspicious for high grade urothelial carcinoma, positive for high grade urothelial
200	carcinoma) ¹² .

201

202 Table 1: Patient and Specimen Cohort Characteristics

	Overall
Number Specimens	1252
Voided (%)	1103 (88.1)
Prior History Hematuria (%)	171 (13.7)
Diagnosis (%)	
Negative for High Grade	810 (64.7)
Urothelial Carcinoma	
Atypical Urothelial Cells	296 (23.6)
Suspicious for High Grade	98 (7.8)
Urothelial Carcinoma	
Positive for High Grade	48 (3.8)
Urothelial Carcinoma	
Contains Artifact (%)	265 (21.2)
Number Patients	140
Age (mean (SD))	71.19 (12.37)
Sex = M(%)	106 (75.7)

203

204 Methods Overview

- 205 In this section, we summarize improvements introduced in AutoParis-X, which will be
- 206 elaborated on in following sections. AutoParis-X was written using the Python programming
- 207 language and neural networks were implemented using the PyTorch and Detectron2 frameworks
- 208 ^{50,51}. Statistical and machine learning models were implemented in Python and R ^{52–54}. A
- 209 graphical overview is provided in Figure 1:

210	1.	Slide processing- Connected components analysis to isolate individual cells and cell
211		clusters, sped up through parallel processing ⁵⁵ .
212	2.	Cell border detection (BorderDet)- Isolates cells within urothelial clusters with
213		overlapping cytoplasmic borders through neural network detection model ⁴⁴ .
214	3.	Cell-Level Measures:
215		a. Morphometric measures- Additional morphological features to improve cell-
216		type classification and atypia estimation (e.g., size / area).
217		b. Urothelial Classifier (UroNet)– Used to filter urothelial cells from potentially
218		conflated cell types through a convolutional neural network, which operates on
219		images of cells and their morphometric measures ⁵⁶ – trained on an expanded
220		dataset with more cell classes.
221		c. NC ratio estimation (UroSeg)- Estimates the NC ratio by neural network pixel-
222		wise segmentation of background, nucleus and cytoplasm. Used as objective
223		marker of atypia.
224		d. Atypia score (AtyNet)– For predicted urothelial cells at a particular cutoff
225		threshold, a subjective score which incorporates multiple screening criteria (e.g.,
226		hyperchromasia, etc.) is determined using another convolutional neural network
227		which operates on images of cells and their morphometric measures and outputs
228		an atypia score ⁴⁸ .
229	4.	Cell- and Cluster- Slide-level scores- Established through a combination of the above
230		scoring methods, counting the number of cells/clusters in the slide with atypical
231		morphology / cluster architecture as defined by previous works ^{43,48} . Optimal decision

232	cutoffs for determining cellular/cluster atypia were decided using Bayesian Optimization	on
233	techniques ⁵⁷ .	

234	5.	Classifier development- Machine learning classifier which integrates cell and cluster
235		level scores and other demographic/specimen characteristics into an Atypia Burden Score
236		(ABS), accounting for repeat measures by patient ^{58–64} .
237	6.	Model interpretation – A hierarchical logistic regression model was constructed from
238		the machine learning model to identify important indicators of atypia, in addition to
239		analogous univariable models. Helpful graphical displays were generated through an
240		interactive web application ⁶⁵ .

241 7. Demo- A demo was deployed to an Amazon Web Services (AWS) server and software
242 released through GitHub and PyPI.

243

244 Slide Preprocessing

245 As detailed in a previous work, individual objects in the image were identified through a 246 connected component analysis ⁴⁸. In brief, WSI were converted into grey scale images using opencv2 in Python (version 3.8)⁶⁶. The background of WSIs were converted to white through 247 248 intensity thresholding of the grey scale image to form an object mask. Small objects, defined as a 249 pixelwise area of 50 or below, were filtered using the *remove small objects* (*scipy*, Python v3.8) 250 morphological operation ⁶⁷. Large objects (e.g., ink markings) were similarly filtered as defined 251 by a minimal area of 500,000 pixels. After small and large object removal, holes within the 252 object mask were filled through the *fill voids* function (which is faster than offerings from the 253 scipy package) ⁶⁸. We leveraged the *cupy* package (Python v3.8) to reduce compute time through 254 usage of Graphics Processing Units (GPU) where appropriate after extensive timing tests ⁶⁹.

Subimages of slide objects (e.g., candidate urothelial cells and clusters) were returned using the scipy regionprops function, which also returned various other morphometric measures and bounding boxes. Inference time and memory usage for the connected component analysis for object identification was reduced through distributed computing procedures (e.g., *Dask*), which use optimized parallelization to operate on larger-than-memory arrays. Using multiprocessing through *dask*, operations were also parallelized across subregions within the slide ⁵⁵.

261

262 Cell Border Identification for Cell Cluster Analysis

263 To improve detection of individual cells within clusters, we previously developed a cell detection 264 neural network, BorderDet, (using the state-of-the-art Detectron2 framework) to identify: 1) 265 location of cells through estimation of bounding boxes (one box per cell) and 2) identify cell 266 boundaries by separating overlapping cytoplasm from adjacent cells. BorderDet was developed 267 using cell clusters identified from the *cluster-level training cohort*. In brief, two cytopathologists 268 (LJV and XL) annotated 800 cell cytoplasmic boundaries for squamous cells, inflammatory cells, 269 negative/atypical urothelial cells, and dense regions of overlapping/indistinguishable cell borders 270 (dense region). BorderDet is an object detection neural network that can detect multiple 271 objects/instances (i.e., cells) in a cell cluster image ⁴⁴. It looks for areas in the image that may 272 contain an object and then assigns a score that indicates how likely it is that the region contains 273 an object. The program labels identified objects with the appropriate label (e.g., squamous cell, 274 dense region) and draws a line around the edges of the object (i.e., segmentation mask) to portray 275 the exact boundary, which can overlap with adjacent cells. This allows the program to accurately 276 identify and locate multiple objects in a single cluster. Objects were then filtered using non-max

suppression, a technique which ranks overlapping objects, as defined through their intersection
over union (IoU), based on their "objectness" score and removes objects with a lower score ⁷⁰.

To reduce the number of objects assessed using BorderDet, a size filter was enforced, assessing candidate cell clusters with a pixelwise area of at least 1800 pixels, determined through a sensitivity analysis and visual inspection. Parallel processing through multithreading and multiprocessing was integrated using *dask* for rapid evaluation ⁵⁵. Individual cells extracted through the connected component analysis (area between 256 and 1800 pixels) and objects extracted from clusters using their instance segmentation masks were further assessed using

single-cell algorithms which report quantitative metrics of atypia (cell-level measures).

287

288 In comparison to the density-based clustering approach that validated urothelial clusters using a 289 CNN (Sanghvi et al.), which could lead to many false negative findings (i.e., approach only 290 "screens out" candidate cell clusters), urothelial cell clusters were identified by BorderDet if they 291 contained urothelial cells ⁴³. This approach improves on watershedding (AutoParis v1) and 292 density-clustering (Sanghvi et al.) techniques as these two methods do not precisely identify cells 293 within larger candidate clusters ^{20,43,44,48}. BorderDet also improves upon previous methods by 294 locating dense urothelial cell architectures with overlapping indistinguishable cytoplasmic 295 borders which are challenging to assess for individual cells. Furthermore, while presence of a 296 dense architectural region in a cluster as defined by an area cutoff was used as an atypia 297 predictor, dense architectures themselves were further subclassified as atypical if surrounding 298 urothelial cells were labeled as atypical (as defined by morphology).

299

300 Cellular Morphometric Measures

301 Various morphometric features were estimated from individual candidate cells, including: 1) 302 area; 2) convex area; 3) eccentricity; 4) equivalent diameter; 5) extent; 6) Feret's diameter; 7) 303 maximum diameter; 8) filled area; 9) major axis length; 10) minor axis length; 11) perimeter; 304 and 12) solidity, extracted using *scikit-image* (Python v3.8) ^{56,71}. These morphometric features 305 were primarily used to help demarcate urothelial cells. As an example, urothelial cells are 306 significantly larger than leukocytes, so cell area is an important criterion for separating the two 307 cell types. Morphometric features were standardized using quantile transformation (implemented 308 in *scikit-learn*, Python v3.8) within the training set to reduce the influence of any given cell on specifically which morphometric features were important for the assessment ⁷². This places 309 310 greater emphasis on the imaging findings as means to delineate between different cell types.

311

312 Urothelial Cell Classification

313 Urothelial cell classification was accomplished using UroNet, which was modified significantly 314 from its original incarnation. While AutoParis estimated both the presence and atypia of the urothelial cell simultaneously ⁴⁸, as differentiated from several other specimen constituents, 315 316 AutoParis-X is chiefly focused on delineating urothelial cells from potentially conflated cell 317 types and slide objects prior to estimating atypia. When aiming to validate the AutoParis 318 algorithm, we noticed that a nontrivial number of urothelial cells lacked a nucleus, potentially 319 related to being out of focus (no Z-stacking)⁷³, but were not included in our original training set 320 and thus were often confused with other cell types with a smaller nuclear area (e.g., squamous 321 cells). We also identified rare urothelial cells with changes consistent with a Polyomavirus

cytopathic effect ^{49,74}. These cells are benign but assessment can often mimic HGUC and would
 certainly mislead any attempt to accurately predict the NC ratio and are thus removed by UroNet.
 324

325 A total of 108,388 and 27,097 cells were manually labeled by two cytopathologists (LJV and XL) 326 and used to train and validate the cell level model respectively from the *cell-level training and* 327 validation cohort. A breakdown of cell types present in this training and validation cohort is listed 328 in Table 2. These cell images were combined into the following classes: 1) urothelial cells 329 (benign/atypical), 2) urothelial cells with polyomavirus cytopathic effect, 3) debris, crystals and 330 red blood cells (RBC), 4) leukocytes, 5) clusters of leukocytes, and 6) squamous cells. UroNet was 331 developed using a residual neural network (ResNet18), augmented with an auxiliary layer which 332 combines the morphometric information (e.g., area/size, eccentricity, etc.) with features extracted 333 from ResNet18 by fusing the penultimate layer of the network with this information. The auxiliary neural network first maps the number of morphometric features, $\overrightarrow{x_M}$, to the number of ResNet18 334 features using a multi-layer perceptron, f_{ϕ} . Then the morphometric information (same 335 336 dimensionality as the ResNet features) is fused with the deep learning features using a gated 337 attention operation, which decides dynamically on a cell-by-cell basis which set of features (deep learning, $\overrightarrow{z_{DL}}$, vs morphometric, $\overrightarrow{z_M}$) to weight more. The weight is dynamically determined using 338 339 the gating neural network, f_{θ} ⁷⁵.

340

0
$$\overrightarrow{z'} = \alpha_{DL} \overrightarrow{z_{DL}} + \alpha_M \overrightarrow{z_M}$$

341
$$\alpha_{DL} = \frac{\exp(a_{DL})}{\exp(a_{DL}) + \exp(a_{M})}; \alpha_{M} = \frac{\exp(a_{M})}{\exp(a_{DL}) + \exp(a_{M})}$$

342
343
$$a_{DL} = f_{\theta}(\overline{z_{DL}}); a_{M} = f_{\theta}(\overline{z_{M}})$$

$$\overline{z_{M}} = f_{\phi}(\overline{x_{M}})$$

344

This operation permits UroNet to filter out cells with significant size differences (e.g., leukocytes are much smaller than urothelial cells). After model training using the *PathflowAI* package ⁷⁶, the

performance of UroNet was assessed using the *cell-level validation set* through the area under the receiver operating characteristic curve (AUC), reported for each class. To assess how much weight was placed on the morphometric features for prediction, we investigated the attention weights, α , across the validation set. We used Integrated Gradients ^{77,78}, a deep learning interpretation method, to assess which specific image/deep learning and morphometric features were important for each cell type.

- 353

Table 2: Number of cell types used to train/validate UroNet and AtyNet

	Benign Urothelial Cells	Atypical Urothelial Cells	Polyomavirus Infected Cells	RBC	Crystals	Debris	Leukocyte	Leukocyte Cluster	Squamous Cells
Training	3522	3795	3606	11199	220	63317	8037	3425	11267
Validation	880	949	901	2800	55	15830	2009	856	2817

355

356

357 NC Ratio Estimation

358 For cells classified as urothelial, the NC ratio was calculated for both *isolated* and *cluster cells*

359 using a segmentation neural network, UroSeg, which employed a U-Net architecture to assign on

360 a pixelwise basis the presence of nucleus, cytoplasm, or background ^{48,79,80}. These areas were

annotated/outlined by cytopathologists and UroSeg was trained and validated on 3,690 and 1,231

362 urothelial cells respectively. Performance was reported using the area under the receiver

363 operating characteristic curve (AUC), reported on a pixelwise basis. For select cell clusters, we

364 compared the impact of running BorderDet, followed by UroNet and UroSeg to calculate the NC

365 ratio as compared to running UroSeg then watershedding, as was originally done by the previous

366 AutoParis algorithm.

367

368 Atypia Score

369	Severa	al cytopathologists determined whether every urothelial cell extracted from the <i>cell-level</i>
370	trainii	ag and validation cohort (Table 2) was benign or atypical, based on existing markers of
371	atypia	(e.g., presence of nuclear membrane irregularity, abnormal chromatin, hyperchromasia,
372	etc.).]	From this information, AtyNet, a CNN based on ResNet18 with a similar architecture as
373	UroNe	et, was trained to recapitulate these subjective findings ⁸¹ . For every urothelial cell, AtyNet
374	calcula	ates a subjective marker of atypia- the atypia score- which is a value from 0-1 that reflects
375	the pro	obability that a cell is atypical. We used IntegratedGradients, a deep learning interpretation
376	metho	d, to assess which specific image/deep learning and morphometric features were important
377	for aty	pia assignment.
378		
379	Calcu	lation of Cell and Cluster Slide-Level Scores
380	All ex	tracted individual cell and cluster level statistics are placed into Rich Information Frames
381	(RIF),	which are data frame/tabular data structures ⁴⁸ . For any given WSI, there are three RIFs
382	(see T	able 3 for description of features):
383	1.	Isolated-Cell-RIF: Stores morphometric measures; bounding box locations within
384		specimens, cell type assignment probabilities; NC ratios; and atypia scores for each cell
385		not associated with clusters (isolated urothelial cells).
386	2.	Cluster-Cell-RIF: Stores morphometric measures; bounding box locations within
387		specimens; cell type assignment probabilities; NC ratios; and atypia scores for each cell
388		associated with clusters, in addition to their cluster assignment label (cluster urothelial
389		cells).
390	3.	Cluster-RIF: Stores bounding box locations within WSI; cluster size; cytoplasmic
391		borders; area of dense regions in cluster; and associated cluster label/identifier.

Information on cellular atypia (e.g., number of atypical cells), number of urothelial cells,
amongst other cluster-level measures, were added to this *RIF* from the *Cluster-Cell-RIFs*.

395	All RIFs are cross-tabulated to form a Slide Inference Frame (SIF), which represents slide-level
396	statistics, aggregated across all urothelial cells and urothelial cell clusters. This is accomplished
397	by thresholding the cutoff probabilities for the cell and cluster-level scores and counting the
398	number of cells and clusters which meet these criteria. For instance, given an atypia score cutoff
399	of 0.7 (i.e., cell is atypical if AtyNet assigns a 70% probability), a cluster is deemed to exhibit
400	cellular atypia if, for instance, more than 20% of the cells within the cluster are atypical under
401	this definition. Based on the definition of a urothelial cluster (e.g., number of urothelial cells),
402	the number of atypical clusters within the WSI can be estimated. All urothelial cells with an NC
403	ratio of 0 were removed prior to calculating these scores. SIF contains the following statistics:
404	1. Isolated cell subscores: Derived from Isolated-Cell-RIF, for cells which were not
405	associated with clusters, including the following statistics: 1) number of urothelial cells;
406	2) number of atypical urothelial cells as determined using the atypia score; 3) number of
407	atypical urothelial cells as determined using the NC ratio; 4) number of urothelial cells;
408	and 5) center and spread of various morphometric measures.
409	2. Cluster cell subscores: Derived from Cluster-Cell-RIF. Similar to isolated cell subscores,
410	only considering cells which were associated with / identified within clusters.
411	3. All cell subscores: Combines isolated and cluster cell subscores, considering all cells,
412	irrespective of whether there was a cluster assignment.
413	4. Cluster subscores, representing aggregate <i>Cluster-RIF</i> statistics, including: 1) number of
414	urothelial clusters (defined by a minimum threshold of urothelial cells); 2) number of

415 atypical urothelial clusters (defined by either NC ratio or <i>atypia</i> score); 3) num
--

- 416 dense clusters; and 4) number urothelial clusters that are both atypical and dense. Unlike
- 417 the previous three scores which focus on individual urothelial cells, identified urothelial
- 418 cell clusters represent the principal unit of analysis.
- 419
- 420 Using AutoParis-X, *RIF-SIF* scores were calculated across the *slide-level training and*
- 421 *validation cohorts*. We added the following patient-level characteristics to the *RIF-SIF* scores: 1)
- 422 age; 2) sex; 3) history of hematuria; and 4) specimen source ^{82,83}. We also noted where slides
- 423 contained significant blood, high cellularity, acellularity, neobladders (abundant degenerated
- 424 enterocytes) and scanning artifacts.
- 425

426 Table 3: Cell/Cluster/Slide-Level Features and their descriptions

Level	Predictor	Algorithm	Description
Cell	Urothelial cell	UroNet	Predicted probability of urothelial cells from convolutional neural network, used to dynamically isolate urothelial cells in specimen
	Atypia score	AtvNet	Predicted probability of presence of atypical features in urothelial cell (e.g.
		Atyrict	hyperchromasia, irregular nuclear membrane, etc.), determined using convolutional neural network
	NC Ratio	UroSeg	Nuclear to cytoplasm area ratio derived from pixelwise segmentation of nucleus and cytoplasm using segmentatio neural network
	Morphometric measures	Custom	Complements binning of urothelial cells and assignment of atypia score, features: 1) area; 2) convex area; 3) eccentricity; 4) equivalent diameter; 5) extent; 6) Feret's diameter; 7) maximum diameter; 8) filled area; 9) major axis length; 10) minor axis length; 11) perimeter; and 12) solidity
Cluster	Dense Area	BorderDet	Whether cluster contains dense architecture of overlapping and indistinguishable cytoplasmic borders
	Number urothelial cells	BorderDet/U roNet	Whether cluster contained urothelial cells, determined by counting cells with high urothelial cell score
	Number atypical urothelial cells (atypia score)	BorderDet/U roNet/AtyNe t	Whether cluster contained abnormal urothelial cells, determined by counting cells with high atypia score
	Number atypical urothelial cells (NC ratio)	BorderDet/U roNet/UroSe g	Whether cluster contained abnormal urothelial cells, determined by counting cells with high NC ratio
	Dense & Atypical	BorderDet/U roNet/AtyNe t/UroSeg	Whether cluster contained both dense architecture and atypical cellular features
Slide	Patient characteristics	Supplied	Includes age, sex, history of hematuria, specimen source (e.g., voided), presence of specimen artifact
	Isolated Cell- SIF Scores	Bayesian Optimization	Counting the number of cells with the following features from cells not associated with clusters: 1) cellularity (urothelial score), 2) atypia (atypia score), 3) atypia (NC ratio), 4) other morphometric measures

Cluster Cell-SIF	Bayesian	Counting the number of cells with the following features from cells associated with
Scores	Optimization	clusters: 1) cellularity (urothelial score), 2) atypia (atypia score), 3) atypia (NC
		ratio), 4) other morphometric measures
All Cell-SIF	Bayesian	Combines Isolated Cell-SIF Scores and Cluster Cell-SIF Scores
Scores	Optimization	
Cluster-SIF	Bayesian	Counting the number of clusters with the following features: 1) number of urothelial
	Optimization	clusters, 2) atypical urothelial clusters (atypia score), 3) atypical clusters (NC ratio),
		4) dense clusters, 5) dense and atypical clusters
Atypia Burden	Mixed	Integrates all slide-level predictors using machine learning model to calculate a score
Score	effects	between 0-1 reflecting overall specimen atypia, correlated with UC diagnostic
	machine	category
	learning	

427

428 **Estimating Specimen Atypia with Machine Learning**

429 Specimen atypia was reported through dichotomization of TPS categories into the following

- 430 classes: 1) negative, atypical and 2) suspicious, positive. The Atypia Burden Score (ABS) reflects
- 431 the predicted probability of a specimen being atypical as assessed by AutoParis-X. We

432 implemented several machine learning and statistical modeling approaches to predict specimen

433 atypia, including: 1) generalized linear mixed effects modeling (hierarchical logistic regression;

- 434 GLMM; brms package, R v4.1), accounting for patient- and pathologist-level random intercepts,
- 435 2) Random Forest, which does not account for clustering by patient, 3) Gaussian Process Tree

Boosting (GPBoost), and 4) Bayesian Additive Regression Trees (BART) ^{58-61,64}. GPBoost and 436

437 BART account for clustering by patient by fitting patient- and pathologist-level random

438 intercepts while capturing interactions and nonlinear associations between SIF predictors using

- 439 ensemble tree models, $f_{\theta}(\vec{x})$:
- 440

442

$$y_i \sim Binomial(1, p_i)$$

441
$$logit(p_i) = \beta_0 + f_{\theta}(\vec{x}) + \beta_1 age_i + \beta_2 sex_i + \beta_3 hematuria_i + b_{patient[i]} + b_{pathologist[i]}$$

442
443
444
444
444

$$b_{patient[i]} \sim N(0, \tau_1^2)$$

 $b_{pathologist[i]} \sim N(0, \tau_2^2)$
 $\beta \sim N(0, \nu^2)$

444

445 446 Overall model performance was communicated using fivefold cross-validation, which randomly 447 partitions the data into a training and validation set and reports the overall performance (using 448 the AUC) over the validation folds. Specimens belonging to the same patient were partitioned

449into the same training/validation fold for each cross-validation split to avoid potential inflation of450test statistics. Confidence intervals (CI) were reported using 1000-sample nonparametric451bootstrapping of each fold to yield 1000 samples of cross-validation statistics. Cell and cluster-452level thresholds (e.g., atypical cell if NC>0.7; atypical cluster if at least 3 urothelial cells are453atypical), which are used to generate *RIF-SIF* scores, were optimally aligned with specimen454atypia through a Bayesian Optimization routine 57 .

455

456 Interpretation

457 We identified significant ABS predictors by extracting salient interactions from the tree ensemble 458 models and reporting odds ratios (OR) from univariable and multivariable Bayesian GLMM models: $logit(p_i) = \vec{\beta} \cdot \vec{x} + b_{patient[i]} + b_{pathologist[i]}$. As many of the ABS predictors were 459 460 highly multicollinear, variance inflation factors and horseshoe lasso priors were used to select predictors ^{84,85}. Univariable associations adjusting for age, sex and hematuria were reported to 461 462 give credence to omitted collinear predictors in the multivariable statistical modeling. 463 Hierarchical Bayesian cumulative link models (i.e., ordinal regression) in a similar specification 464 were also used to report associations between the predictors and specimen atypia, treating the 465 urine cytology assignment as an ordinal variable ^{86,87}. Statistical significance was reported using the p-value, as derived from the probability of direction (*pd*): $p \approx 2 * (1 - pd)$. A p-value less 466 467 than 0.05 indicates a significant atypia predictor. Credible intervals, similar to confidence 468 intervals, communicated uncertainty in the effect estimates.

469

470 Web Application and Software Availability

471	We also developed an interactive web application which allows for rapid assessment of cytology
472	slides. In brief, users first select a slide to examine. An ABS score is returned for the specimen as
473	assessed using AutoParis-X. The Cell-RIF is converted into a 2D scatter plot of the NC ratio and
474	atypia score- each point represents a cell. Using a "lasso tool", users select cells within this
475	scatterplot. The urothelial cells are highlighted on a zoomable WSI viewer (openseadragon) and
476	additionally made available through an image gallery for additional examination (Figure 2) ⁸⁸ .
477	The WSI viewer will highlight cells based on their relative degree of atypia as assessed
478	algorithmically, focusing the end-user on a small subset of potentially malignant cells. A demo
479	of this interactive web application can be found at the following URL:
480	http://edit.autoparis.demo.levylab.host.dartmouth.edu/ (user: edit_user, password: qdp_2022;
481	full-screen display is encouraged for optimal viewing experience). The web application also
482	features a tutorial video for operating the application. The AutoParis-X software is also open-
483	source, available to download on GitHub (<u>https://github.com/jlevy44/AutoParisX</u>) and installable
484	using the following PyPI package: autoparis. Users aiming to run AutoParis-X will need to train
485	compatible neural networks as neural networks were only trained on data from a single
486	institution and would need additional finetuning to generalize.





Figure 2: AutoParis-X Web Application: A) Cytopathologist selects patient/specimen scanned and processed the previous day, which outputs Atypia Burden Score; **B)** Urothelial cells are identified based on a cutoff probability selected by the user; **C)** Individual cells are plotted using scatter plot, which depicts each cell's NC ratio and atypia score; user selects most atypical cells for viewing via the WSI viewer and gallery using the "Lasso" tool; **D)** WSI viewer– red points are sized by degree of atypia and identify important urothelial cells to assess/zoom in; **E)** gallery view enables rapid examination of individual cells, sorting them by their degree of atypia

496 **Results**

497 **Performance of UroNet**

498 UroNet demonstrated remarkable performance in the task of delineating among 6 different

499 classes of cell types / objects to determine which cells are urothelial (Figure 2; Table 4). Figure

500 **3A** demonstrates a nearly perfect ROC curve (AUC=0.997 macro-averaged) for all 6 cell types

501 across the validation set, indicating high classification accuracy. In addition, raw imaging

502 features interpreted using IntegratedGradients corroborated with known histomorphology for

- 503 specific cell types (e.g., highlighting dense chromatin to depict urothelial cells, surrounding
- 504 membrane for squamous cells, etc.; Figure 3B). Many morphometric features were found to be
- 505 important– for instance: 1) eccentricity as a defining feature of urothelial cells versus other cell



512



514 Figure 3: Performance of UroNet/UroSeg/AtyNet: A) Receiver operating characteristic curves 515 for each cell type from the internal validation set (UroNet) and for delineating atypical versus 516 benign urothelial cells (AtyNet); B) Integrated Gradients heatmap localizing important features 517 identified using UroNet for urothelial cells, squamous cells and leukocyte clusters; C) Integrated 518 Gradients heatmap localizing important features identified using AtyNet for one benign 519 urothelial cell / cell cluster, followed by two atypical cell images; **D**) Example ground truth 520 segmentation masks (left; background- black, cytoplasm- red, nucleus- yellow), original images 521 (center) and segmentation masks predicted using UroSeg (right); E) Receiver operating 522 characteristic curves for background, cytoplasm and nucleus (pixelwise assessments) from the internal validation set (UroSeg); F) Ground truth versus UroSeg predicted NC ratios. derived 523 524 from the segmentation results

525

Algorithm	Quantity	Measure	Estimate	2.5% CI	97.5% CI
UroNet	Urothelial	AUC	0.994	0.993	0.995
	Polyomavirus	AUC	0.996	0.995	0.996
	Debris, Crystals, RBCs	AUC	0.998	0.998	0.998
	Leukocytes	AUC	0.997	0.996	0.998
	Leukocyte Clusters	AUC	0.997	0.996	0.997
	Squamous Cells	AUC	0.998	0.998	0.999
AtyNet	Atypia Score	AUC	0.917	0.905	0.929
UroSeg	Background	AUC	0.993	0.993	0.993
	Cytoplasm	AUC	0.977	0.977	0.977
	Nucleus	AUC	0.944	0.944	0.944
	NC Ratio	Spearman	0.965	0.954	0.973
		Mean Absolute Error	0.015	0.014	0.017

526 **Table 4**: **Performance Statistics for UroNet, UroSeg, and AtyNet**; 95% confidence intervals 527 estimated using 1000-sample non-parametric bootstrapping

528 529

530 Performance of UroSeg

531 UroSeg, a neural network segmentation tool, demonstrated excellent performance on our internal

validation set in predicting the pixelwise presence of the nucleus and cytoplasm (AUC=0.971

533 macro-averaged) in order to calculate nuclear to cytoplasm (NC) ratio (Figures 2-3; Table 4).

534 Figure 3F also shows nearly perfect receiver operating characteristic curves for both the nucleus

and cytoplasm, indicating the high accuracy of UroSeg in predicting these structures.

536 Additionally, we found that the NC ratios calculated from the segmentation masks produced by

537 UroSeg correlated nearly perfectly with the ground truth NC ratios (r=0.965; MAE=0.015)

annotated by the cytopathologists (Figure 3G). Figure 3E demonstrates the alignment of the

true and predicted nuclear and cytoplasmic segmentation masks, further highlighting the

540 accuracy of UroSeg.

542 UroSeg was similarly effective when used in conjunction with BorderDet, our previously 543 established urothelial cluster border separation tool. Cells extracted from urothelial clusters using 544 BorderDet and confirmed to be urothelial via UroNet were assessed using UroSeg. We compared 545 the NC ratios, averaged across each urothelial cluster, in our internal validation set with what 546 was accomplished using watershedding techniques (which divided the clusters after seeding the 547 watershed based on the location of the nuclei). Watershedding was not sensitive to the cell type 548 as it did not leverage BorderDet and UroNet. In addition, for clusters containing urothelial cells 549 and background debris or other confounding cell types, watershed heavily underestimated the 550 NC ratio (Figure 4). This was universal across all of the urothelial clusters in the internal 551 validation set. Through visual examination, it is clear that by precisely demarcating cytoplasmic 552 borders between immediately adjacent and overlapping cells, BorderDet and UroNet allow for 553 precise estimation of the NC ratio. Opting for alternative assessment approaches (e.g., 554 watershedding) could reduce the predictive capacity of slides containing abundance of urothelial 555 cell clusters by removing or unnecessarily skewing the reported statistics for these cells as 556 compared to isolated cells. 557





560 Figure 4: Performance of BorderDet and UroSeg on estimating NC ratios for cells in 561 clusters: A) Estimates derived using watershedding underestimate the NC ratio, whereas 562 detecting the urothelial cytoplasmic borders then using UroSeg (segmentation masks plotted over 563 detected urothelial cells) to estimate the NC ratio leads to a higher and more accurate NC ratio; 564 final cluster contains dense region of significantly overlapping and indistinguishable cytoplasmic 565 borders, dense area used as a predictor for AutoParis-X; B) Scatterplot comparing watershed-566 derived and BorderDet derived NC ratios; C) Shift plot indicating BorderDet NC ratios are 567 higher than that achieved using watershedding

568

569 **Performance of AtyNet**

570 Performance for AtyNet, the neural network which provides an atypia score estimate for each

571 urothelial cell, was equally promising (Figure 2; Table 4). The algorithm achieved an area under

- 572 the receiver operating characteristic curve of 0.917 on the internal validation set, indicating a
- 573 strong ability to distinguish between atypical and normal cells. Model interpretation using
- 574 integrated gradients revealed that the algorithm placed a high emphasis on irregularities in the
- 575 nuclear membrane as a key feature in determining cytological atypia (Figure 2B) ⁵⁶.

576

577 ABS Classifier Performance

578	Individual cell and cluster level features were cross tabulated across the slide and assessed using
579	multiple statistical and machine learning algorithms. Many cellular and cluster level features
580	correlated closely with specimen atypia (Supplementary Figures 2-4). Atypical urothelial cells
581	as defined by both the NC ratio and atypia score, which were contained within clusters were, in
582	some cases, more predictive of specimen atypia than assessment of isolated cells alone (e.g.,
583	cells with high NC ratio in clusters were more predictive than isolated cells with high NC ratio),
584	further suggesting the importance of employing BorderDet for separating cells. The number of
585	urothelial cells and cell clusters correlated directly with potential for malignancy. Urothelial cell
586	clusters which were both atypical and contained dense regions were the third most predictive
587	variable when assessed using univariable regression.
588	
589	As part of the AutoParis-X framework, each machine learning model outputs the Atypia Burden
590	Score (ABS)- the probability of assigning suspicious or positive UC exam as judged using
591	AutoParis-X. Across all algorithms, ABS correlated closely with specimen atypia. The machine
592	learning models which accounted for patient and pathologist-level variation, GPBoost and
593	BART, outperformed all other approaches with AUCs of 0.89 and 0.88 respectively (Figure 5A;
594	Table 5). The generalized linear mixed effects models also performed well. Across all models,
595	ABS scores preserved the ordering of the UC categories
596	(Negative <atypical<suspicious<positive; 5b).="" an="" figure="" fit="" model="" ordinal="" regression="" td="" this<="" to="" we=""></atypical<suspicious<positive;>
597	data, which demonstrated a strong positive association with atypia (UC categories; β =
598	3.61; 95% <i>CI</i> : $[3.12 - 4.11]$; $p < 0.0001$). This information is corroborated by density heatmaps
599	depicting the NC Ratio and Atypia score for individual urothelial cells across the entire cohort,
600	after being filtered using UroNet. This yielded more than 6 million cells, which were separated

based on their UC class. Figure 5D demonstrates the progression in cellular atypia across the

602 categories-negative cases typically do not contain cells that have both high NC ratio and atypia,

603 while these cells can be increasingly found at higher UC categories. Positive cases contain many

- 604 cells that are both highly atypical with high NC ratio.
- 605



Age Age:Atypia Hematuria isolated Aty Clusters Clusters NC Ratio
Figure 5: ABS Classifier Performance: A) Receiver operating characteristic curves illustrating
performance of ABS classifiers; B) Boxplot of raw ABS scores predicted by GPBoost and
Random Forest by UC class; C) Point estimates and 95% credible intervals for predictors
uncovered from final multivariable Bayesian hierarchical model; D) Density plot of NC Ratios
and Atypia scores cross tabulated across over 6 million cells from the retrospective cohort,
divided by UC classes, demonstrating progression of cells to take on higher NC ratios and Atypia

- 614
- Table 5: Performance statistics for ABS Classifiers; 95% confidence intervals estimated using
 1000-sample non-parametric bootstrapping

	AUC	2.5% CI	97.5% CI
RF	0.873	0.846	0.897
GPBoost	0.889	0.866	0.913
BART	0.876	0.847	0.901
BGLMM	0.833	0.788	0.873
BGLMM-Int	0.843	0.808	0.874

Parameter	OR	2.5% CI	97.5% CI	p-value
Number of Clusters	1.31	1.06	1.68	0.016
Age	1.57	1.07	2.39	0.029
History of Hematuria	1.40	1.17	1.69	0.003
Dense/Atypical Clusters	1.84	1.41	2.39	< 0.001
Number Isolated Atypical Cells	1.81	1.32	2.44	< 0.001
Age:Number Isolated Atypical Cells	0.80	0.65	0.99	0.050

Table 6: Effect estimates, 95% credible intervals and p-values for multivariable regression model

620

621 Univariable and Multivariable associations with Specimen Atypia

622 **Table 6** demonstrates the importance of the individual slide level predictors through both

623 univariable and multivariable regression modeling. A few predictors remained in the unpenalized

624 statistical model after applying the horseshoe lasso (Figure 5C). This included positive

625 associations with number of clusters, number of both atypical and dense clusters, number of

626 isolated atypical cells and an interaction between age and atypia. The interaction demonstrates

627 that overall specimen atypia younger individuals more greatly impacted by number of atypical

628 urothelial cells as compared to older individuals.

629

630 Web Application Example

631 As a demonstration of Autoparis-X's ability to facilitate rapid examination of UC specimens, we

632 examined four specimens with the web application (see Supplementary Figures 5-7 for

633 screenshots). Among thousands of specimens examined using this web tool, select cases

634 (negative, atypical, suspicious, positive) can be further inspected using the demo application (see

635 Web Application and Software Availability). The first case (Supplementary Figure 5)

- 636 yielded an Atypia Burden Score of 0.14. Urothelial cells were selected with high atypia and were
- 637 plotted on the WSI, revealing their locations. Zooming in on the WSI confirmed the reported
- 638 cell-level statistics. We also used the table as means to rapidly examine all atypical cells in order

639 of decreasing atypia as a faster method to examine cells versus zooming in using the web 640 application. These examinations confirmed that this was in fact an atypical specimen. The 641 second case produced an atypia burden score of 0.6- a similar examination revealed specimen 642 atypia on par with that of a suspicious assignment. The final case was a positive patient with an 643 atypia burden score of 0.76. We focused on only a few cells which demonstrated the highest 644 potential for malignancy in order to focus our examination given the high cellularity of the 645 specimen. Many of these cells were nested in urothelial cell clusters. This search identified cells 646 which were indeed highly malignant morphologically, allowing for rapid assignment of a 647 positive finding. In **Supplementary Figure 8**, we used the WSI viewer to zoom in on a few 648 malignant cells identified using the AutoParis-X web application. 649 650 Discussion 651 Advances in urine examination from ancient times to the information age have been 652 accompanied by improvements in both specimen preparation and rigorous quantitative bladder 653 cancer screening criteria⁴. Urine cytology (UC) examination for specimen atypia has emerged as 654 the staple of modern-day bladder cancer screening and is often accompanied by more invasive 655 methods for cases demonstrating suspicious or positive classifications. For example, TPS is a 656 widely used grading system in urine cytology screening for bladder cancer, which assigns four 657 main categories based on the presence of high-grade urothelial carcinoma cells and specific 658 cellular features. Yet, despite advances in manual examination methods, there is often poor inter-659 rater variability in the interpretation of atypical or suspicious specimens, and TPS does not include rigorous criteria for evaluating urothelial cell clusters ^{11,17,89–94}. Automation in 660 661 cytopathology can improve the reliability of cytological assessments and help clinicians address

662 growing numbers of tests and avoid diagnostic errors, as has been demonstrated in the 663 gynecologic cytology market with the adoption of systems such as ThinPrep® Imaging System and FocalPoint[™] GS Imaging system ²⁴. Existing systems for semi-autonomous UC examination 664 665 have addressed many existing challenges, though have yet to adequately account for many 666 additional complexities which can confound assessment (e.g., clusters, polyomavirus, etc.)^{20,21}. 667 In this study, we detailed the development of an artificial intelligence tool, AutoParis-X, which 668 improves upon its previous incarnation, to allow for the rapid and nuanced examination of UC 669 specimens; validation on a large-scale retrospective cohort illustrated the maturity and technical 670 sophistication of this tool. For instance, challenges associated with calculation of NC ratios and 671 overall cellular atypia within dense, overlapping urothelial cell clusters were addressed with 672 remarkably good performance ⁴⁴. The importance of many previously understudied predictors 673 were evaluated (e.g., number of atypical and dense urothelial clusters). Finally, the featured 674 interactive web application was designed for ease-of-use for semi-autonomous diagnostic 675 decision making.

676

677 All of these innovations suggest AutoParis-X's potential to greatly facilitate the process of 678 bladder cancer screening, potentially resulting in a significant increase in diagnostic accuracy 679 and a subsequent decrease in potential avenues for error (similar to what occurred with wide adoption of FocalPoint for Pap tests) ^{31,95}. For instance, results suggest that UroSeg can be used 680 681 to accurately calculate NC ratios in a high-throughput manner. AutoParis-X can be used to 682 examine hundreds to thousands of cytology specimens overnight, permitting semi-autonomous 683 evaluation from the cytopathologist via the web application the following day (or in real time as 684 results are generated). This is expected to increase the number and throughput of cytology exams

685 that can be performed by any given institution while accounting for the necessary safeguards 686 (i.e., secondary manual review of random cohort of cases as is now done with Pap tests). Cases 687 unable to be assessed using this web-based platform could be shunted to the classical manual 688 interpretation pathway. With any newly introduced technology, rigorous real-world clinical trials 689 will be required to evaluate the potential impact of adopting this system. As there are only 690 limited applications of AI technologies in digital pathology that have been approved by the FDA 691 for clinical usage, several existing practicalities are worth addressing before AutoParis-X can be 692 safely employed in the clinic. Social barriers for adoption can be identified through surveys on 693 attitudes and beliefs about the tool, which will allow for iterative refinement of the output display 694 and additional algorithmic finetuning. AutoParis-X will also need to demonstrate non-inferiority 695 in a clinical trial (i.e., random assignment of individuals to assessment via manual and semi-696 autonomous examination). As non-inferiority is evaluated with respect to a ground-truth 697 measurement, it will be difficult to prove the utility of AutoParis-X to assign specimen atypia 698 based on alignment to cytopathologist ratings alone given the high inter-observer variation (e.g. 699 there is no universal, quantitative ground truth in urine cytology) ^{12,17,93}. Additional validation 700 will likely require assessment of its capacity to predict more objective outcomes, such as disease 701 recurrence or death 96-99. Additionally, its cost-effectiveness over traditional methods will also 702 need to be proven (e.g., CPT codes, RVUs, number of specimens per day, technologist and 703 pathologist time spent), which will communicate revenue to be expected / workforce needed 704 when operating the device ^{100–103}. A clearer understanding of how these tools can impact clinical 705 decision making is needed before implementation (e.g., what conditions/thresholds are necessary 706 to flag the case for manual review under a microscope) 104 .

707

708 There are several limitations worth noting that will require future improvements and 709 developments. We observed potential scanning artifacts (e.g., pixelation of cells), deficiencies in 710 specimen preparation, high cellular density, and blood in the samples, which complicate the 711 assessment. However, we have not yet developed methods to address these challenges. In 712 addition to surveying attitudes, beliefs and adoption barriers, cytopathologists unfamiliar with 713 digital technologies may favor assessment through analog means (e.g., microscope)- this will 714 either require additional training and education on how to operate these nascent technologies or 715 may require further subspecialization / training of cytopathologists to perform a digital 716 assessment ^{105–109}. AutoParis-X does not account for Z-stacking of cytology slides which can be 717 accounted for in future iterations to model cells in 3D^{73,110}. Annotation of individual cells and 718 clusters were performed by a small group of cytopathologists. Some of these annotations (e.g., 719 nucleus, delineation of cytoplasmic borders in clusters, cell type) may differ between 720 cytopathologists. In addition, data was only collected and validated at a single institution which 721 may limit generalization of these approaches as other institutions may have heterogenous patient 722 characteristics/demographics and different specimen preparation methods ¹¹¹. Additional data 723 collection from multiple institutions can ameliorate these potential challenges by improving the 724 diversity of the dataset, allowing additional flexibility. There is also room for improvement for 725 deriving slide level features. While we utilized Bayesian Optimization to decide which 726 cells/clusters were atypical, dense, clusters, etc., consideration of additional thresholds or forms 727 to summarize this information could improve the model accuracy. There exists a plethora of 728 modeling approaches which can be utilized to predict specimen atypia. For instance, attention 729 and graph-based neural network architectures can take as input the entire WSI broken into 730 constituent cells, each of which has stored attribute/morphological information. and perform

731	what amounts to a weighted average across the cells to derive a final summary statistic ^{112,113} .
732	The ordinal nature of UC class assignment was not explicitly taken into account for most of the
733	results in this study and can be incorporated into these machine learning models using the
734	appropriate model likelihoods ¹¹⁴ . Institutions aiming to adopt these digital technologies will also
735	require significant computing infrastructure. This requires the purchase and utilization of GPU
736	enabled compute nodes (cloud computing services such as AWS and Google Cloud present
737	viable alternatives to in-house purchases), adoption of containerized workflows, which
738	standardize and scale analyses, and hosting of front-facing applications with appropriate
739	databasing, security and credentialling.
740	
741	Conclusion
742	Bladder cancer screening through urine cytology exams is a tedious and fatigable process as
743	cytopathologists assess tens to hundreds of thousands of cells per specimen. Algorithmic
744	techniques to emulate these assessments are beginning to address the incredibly nuanced nature
745	of these assessments. This study featured the design and large-scale validation of a digital
746	diagnostic decision aid, AutoParis-X, which iterates on previous incarnations of urine cytology
747	assessment algorithms to address many remaining complexities associated with challenging
748	examination; further, it features a web application that allows for accurate and rapid examination
749	of specimens. We encourage interested parties to utilize the AutoParis-X workflow and consider
750	validating and finetuning the algorithm for other practice settings to enhance its wider
751	generalizability. The current study demonstrated that quantitative digital urine cytology
752	assessment methods have come of age and are prepared for further rigorous prospective
753	evaluation to investigate its future role in augmenting clinical diagnostic decision making.

755 **References**

- Barkan, G. A. *et al.* The Paris System for Reporting Urinary Cytology: The Quest to
 Develop a Standardized Terminology. *ACY* 60, 185–197 (2016).
- Bostwick, D. G. 7 Urine Cytology. in *Urologic Surgical Pathology (Fourth Edition)* (eds.
 Cheng, L., MacLennan, G. T. & Bostwick, D. G.) 322-357.e7 (Elsevier, 2020).
- Mossanen, M. & Gore, J. L. The burden of bladder cancer care: direct and indirect costs.
 Curr Opin Urol 24, 487–491 (2014).
- Magiorkinis, E. & Diamantis, A. The fascinating story of urine examination: From
 uroscopy to the era of microscopy and beyond. *Diagnostic Cytopathology* 43, 1020–1036
 (2015).
- 5. Salem, S., Mitchell, R. E., El-Alim El-Dorey, A., Smith, J. A. & Barocas, D. A. Successful control of schistosomiasis and the changing epidemiology of bladder cancer in Egypt. *BJU international* 107, 206–211 (2011).
- Botelho, M. C., Alves, H. & Richter, J. Halting Schistosoma haematobium-associated
 bladder cancer. *International journal of cancer management* 10, (2017).
- 771 7. Papanicolaou, G. N. Cytology of the urine sediment in neoplasms of the urinary tract. *The Journal of urology* 57, 375–379 (1947).
- Layfield, L. J., Elsheikh, T. M., Fili, A., Nayar, R. & Shidham, V. Review of the state of the art and recommendations of the Papanicolaou Society of Cytopathology for urinary cytology procedures and reporting: the Papanicolaou Society of Cytopathology Practice Guidelines Task Force. *Diagnostic cytopathology* **30**, 24–30 (2004).
- 9. Wang, Y.-H. *et al.* Diagnostic Agreement for High-Grade Urothelial Cell Carcinoma in
 Atypical Urine Cytology: A Nationwide Survey Reveals a Tendency for Overestimation in
 Specimens with an N/C Ratio Approaching 0.5. *Cancers* 12, 272 (2020).
- 10. Barkan, G. A. Enough is enough: adequacy of voided urine cytology. (2016).
- Roy, M. *et al.* An institutional experience with The Paris System: A paradigm shift from
 ambiguous terminology to more objective criteria for reporting urine cytology. *Cytopathology* 28, 509–515 (2017).
- 12. Levy, J. J. *et al.* Large-scale longitudinal comparison of urine cytological classification
 systems reveals potential early adoption of The Paris System criteria. *J Am Soc Cytopathol*S2213-2945(22)00241-1 (2022) doi:10.1016/j.jasc.2022.08.001.
- 13. Kurtycz, D. F., Wojcik, E. M. & Rosenthal, D. L. Perceptions of Paris: an international
 survey in preparation for The Paris System for Reporting Urinary Cytology 2.0 (TPS 2.0).
 Journal of the American Society of Cytopathology 12, 66–74 (2023).
- Nikas, I. P. *et al.* The Paris System for Reporting Urinary Cytology: A Meta-Analysis.
 Journal of Personalized Medicine 12, 170 (2022).
- Wojcik, E. M., Kurtycz, D. F. & Rosenthal, D. L. *The Paris system for reporting urinary cytology*. (Springer, 2022).
- 16. Wojcik, E. M., Kurtycz, D. F. & Rosenthal, D. L. We'll always have Paris the Paris system
 for reporting urinary cytology 2022. *Journal of the American Society of Cytopathology* 11,
 62–66 (2022).
- 17. Long, T. *et al.* Interobserver reproducibility of The Paris System for Reporting Urinary
 Cytology. *Cytojournal* 14, 17 (2017).

- 18. Landau, M. S. & Pantanowitz, L. Artificial intelligence in cytopathology: a review of the
 literature and overview of commercial landscape. *Journal of the American Society of Cytopathology* 8, 230–241 (2019).
- Pouliakis, A. *et al.* Artificial Neural Networks as Decision Support Tools in Cytopathology:
 Past, Present, and Future. *Biomed Eng Comput Biol* 7, 1–18 (2016).
- McAlpine, E. D., Pantanowitz, L. & Michelow, P. M. Challenges Developing Deep
 Learning Algorithms in Cytology. ACY 65, 301–309 (2021).
- Thiryayi, S. A. & Rana, D. N. Urine cytopathology: challenges, pitfalls, and mimics. *Diagnostic Cytopathology* 40, 1019–1034 (2012).
- 808 22. Jiang, H. *et al.* Deep learning for computational cytology: A survey. *Med Image Anal* 84, 102691 (2023).
- 810 23. Rezende, M. T., Bianchi, A. G. C. & Carneiro, C. M. Cervical cancer: Automation of Pap
 811 test screening. *Diagn Cytopathol* 49, 559–574 (2021).
- 812 24. Okuda, C. *et al.* Quantitative cytomorphological comparison of SurePath and ThinPrep
 813 liquid-based cytology using high-grade urothelial carcinoma cells. *Cytopathology* 32, 654–
 814 659 (2021).
- 815 25. Tolles, W. E. The cytoanalyzer-an example of physics in medical research. *Trans N Y Acad*816 *Sci* 17, 250–256 (1955).
- 817 26. Bourghardt, S., Hyden, H. & Nyquist, B. A scanning and computing microphotometer for
 818 cell analyses. *Experientia* 11, 163–165 (1955).
- 819 27. Abels, E. *et al.* Computational pathology definitions, best practices, and recommendations
 820 for regulatory guidance: a white paper from the Digital Pathology Association. *J Pathol*821 249, 286–294 (2019).
- 822 28. Pantanowitz, L. Improving the Pap test with artificial intelligence. *Cancer Cytopathol* 130, 402–404 (2022).
- Xue, P. *et al.* Deep learning in image-based breast and cervical cancer detection: a
 systematic review and meta-analysis. *NPJ Digit Med* 5, 19 (2022).
- B26 30. Hou, X. *et al.* Artificial Intelligence in Cervical Cancer Screening and Diagnosis. *Front* B27 Oncol 12, 851367 (2022).
- 828 31. Thrall, M. J. Automated screening of Papanicolaou tests: A review of the literature. *Diagn*829 *Cytopathol* 47, 20–27 (2019).
- 830 32. Chantziantoniou, N. BestCyte® Cell Sorter Imaging System: Primary and adjudicative
 831 whole slide image rescreening review times of 500 ThinPrep Pap test thin-layers An intra832 observer, time-surrogate analysis of diagnostic confidence potentialities. *J Pathol Inform*833 13, 100095 (2022).
- Base 33. Delga, A. *et al.* Evaluation of CellSolutions BestPrep® automated thin-layer liquid-based
 cytology Papanicolaou slide preparation and BestCyte® cell sorter imaging system. *Acta Cytol* 58, 469–477 (2014).
- 837 34. Pantanowitz, L. & Bui, M. M. Image Analysis in Cytopathology. in *Monographs in Clinical*838 *Cytology* (eds. Bui, M. M. & Pantanowitz, L.) vol. 25 91–98 (S. Karger AG, 2020).
- 839 35. Pantanowitz, L., Hornish, M. & Goulart, R. A. Informatics applied to cytology. *Cytojournal* 5, 16 (2008).
- 841 36. Wilbur, D. C. Digital cytology: current state of the art and prospects for the future. *Acta*842 *Cytol* 55, 227–238 (2011).
- 843 37. Dov, D. *et al.* Weakly supervised instance learning for thyroid malignancy prediction from
 844 whole slide cytopathology images. *Med Image Anal* 67, 101814 (2021).

- 38. Yao, K. *et al.* A Study of Thyroid Fine Needle Aspiration of Follicular Adenoma in the
 'Atypia of Undetermined Significance' Bethesda Category Using Digital Image Analysis. J *Pathol Inform* 13, 100004 (2022).
- 39. Girolami, I. *et al.* Impact of image analysis and artificial intelligence in thyroid pathology,
 with particular reference to cytological aspects. *Cytopathology* **31**, 432–444 (2020).
- 40. Sanyal, P., Mukherjee, T., Barui, S., Das, A. & Gangopadhyay, P. Artificial Intelligence in
 Cytopathology: A Neural Network to Identify Papillary Carcinoma on Thyroid Fine-Needle
 Aspiration Cytology Smears. *J Pathol Inform* 9, 43 (2018).
- 853 41. Elliott Range, D. D. *et al.* Application of a machine learning algorithm to predict
 854 malignancy in thyroid cytopathology. *Cancer Cytopathol* 128, 287–295 (2020).
- 42. Guan, Q. *et al.* Deep convolutional neural network VGG-16 model for differential
 diagnosing of papillary thyroid carcinomas in cytological images: a pilot study. *J Cancer*10, 4876–4882 (2019).
- 43. Sanghvi, A. B., Allen, E. Z., Callenberg, K. M. & Pantanowitz, L. Performance of an
 artificial intelligence algorithm for reporting urine cytopathology. *Cancer Cytopathology*127, 658–666 (2019).
- 44. Levy, J. J. *et al.* Uncovering additional predictors of urothelial carcinoma from voided
 urothelial cell clusters through a deep learning-based image preprocessing technique. *Cancer Cytopathol* (2022) doi:10.1002/cncy.22633.
- 45. Mahmood, F. *et al.* Deep Adversarial Training for Multi-Organ Nuclei Segmentation in
 Histopathology Images. *IEEE Transactions on Medical Imaging* (2020)
 doi:10.1109/TMI.2019.2927182.
- 867 46. Bankhead, P. *et al.* QuPath: Open source software for digital pathology image analysis. *Sci*868 *Rep* 7, 1–7 (2017).
- 47. Humphries, M. P., Maxwell, P. & Salto-Tellez, M. QuPath: The global impact of an open source digital pathology system. *Computational and Structural Biotechnology Journal* 19, 871 852–859 (2021).
- 48. Vaickus, L. J., Suriawinata, A. A., Wei, J. W. & Liu, X. Automating the Paris System for urine cytopathology—A hybrid deep-learning and morphometric approach. *Cancer Cytopathology* **127**, 98–115 (2019).
- 49. Singh, H. K., Bubendorf, L., Mihatsch, M. J., Drachenberg, C. B. & Nickeleit, V. Urine
 Cytology Findings of Polyomavirus Infections. in *Polyomaviruses and Human Diseases*(ed. Ahsan, N.) 201–212 (Springer, 2006). doi:10.1007/0-387-32957-9 15.
- 878 50. Paszke, A. *et al.* PyTorch: An Imperative Style, High-Performance Deep Learning Library.
 879 *arXiv:1912.01703 [cs, stat]* (2019).
- 880 51. Wu, Y., Kirillov, A., Massa, F., Lo, W.-Y. & Girshick, R. Detectron2. (2019).
- 881 52. Matthes, E. *Python Crash Course, 2nd Edition: A Hands-On, Project-Based Introduction to*882 *Programming.* (No Starch Press, 2019).
- 883 53. Bürkner, P.-C. brms: An R Package for Bayesian Multilevel Models Using Stan. *Journal of Statistical Software* 80, 1–28 (2017).
- 54. Tippmann, S. Programming tools: Adventures with R. *Nature* **517**, 109–110 (2015).
- 886 55. Rocklin, M. Dask: Parallel Computation with Blocked algorithms and Task Scheduling. in
 887 126–132 (2015). doi:10.25080/Majora-7b98e3ed-013.
- 888 56. Harvey, S. E. & VandenBussche, C. J. Nuclear membrane irregularity in high-grade
 889 urothelial carcinoma cells can be measured by using circularity and solidity as

890		morphometric shape definitions in digital image analysis of urinary tract cytology
891		specimens. Cancer Cytopathol (2023) doi:10.1002/cncy.22682.
892	57.	Louppe, G. Bayesian optimisation with scikit-optimize. in <i>PyData Amsterdam</i> (2017).
893	58.	Sigrist, F. Gaussian Process Boosting. Journal of Machine Learning Research 23, 1–46
894		(2022).
895	59.	Sigrist, F. Latent Gaussian Model Boosting. <i>IEEE Transactions on Pattern Analysis and</i>
896		Machine Intelligence 1–1 (2022) doi:10.1109/TPAMI.2022.3168152.
897	60.	Tan, Y. V. & Roy, J. Bayesian additive regression trees and the General BART model.
898		Statistics in Medicine 38 , 5048–5069 (2019).
899	61.	Chipman, H. A., George, E. I. & McCulloch, R. E. BART: Bayesian additive regression
900	011	trees The Annals of Annlied Statistics 4 266–298 (2010)
901	62	Haijem A Bellavance F & Larocque D Mixed-effects random forest for clustered data
902	02.	Journal of Statistical Computation and Simulation 84 1313–1328 (2014)
903	63	Levy I I <i>et al</i> Mixed Effects Machine Learning Models for Colon Cancer Metastasis
904	05.	Prediction using Spatially I ocalized Immuno-Oncology Markers, Pac Symp Riocomput 27
905		175_186 (2022)
906	64	Bürkner P $-C$ Advanced Bayesian Multilevel Modeling with the R Package hrms. The R
907	07.	Journal 10 305 A11 (2018)
008	65	Derkal I M Data visualization tools drive interactivity and reproducibility in online
000	05.	nublishing Nature 554 123 124 (2018)
010	66	Prodeki G. The openCV library Dr. Dobb's Lowrad: Software Tools for the Professional
910	00.	Bradski, O. The opene V horary. Dr. Dobb S Journal. Software roots for the Projessional
911	67	Virtagen D. et al. SoiDy 1.0; fundamental algorithms for scientific computing in Dythen
912	07.	Nature methods 17 , 261, 272 (2020)
915	60	Nature methods 17, 201–272 (2020).
914	08. 60	Silversmith, w. III-voids: Fill voids in 5D binary images fast.
915	09.	Nishino, R. & Loomis, S. H. C. Cupy: A numpy-compatible florary for hydra gpu
910	70	calculations. 51st confernce on neural information processing systems 151, (2017).
91/	/0.	Cheng, B. <i>et al.</i> Panopuc-DeepLao: A Simple, Strong, and Fast Baseline for Boltom-Op
918	71	Panoptic Segmentation. $arXiv: 1911.10194$ [CS] (2020).
919	/1.	Van der Walt, S. <i>et al.</i> scikit-image: image processing in Python. <i>PeerJ 2</i> , e453 (2014).
920	12.	Pedregosa, F. <i>et al.</i> Scikit-learn: Machine Learning in Python. <i>Journal of Machine Learning</i>
921	= 2	Research 12, 2825–2830 (2011).
922	73.	Kim, D. <i>et al.</i> Evaluating the role of Z-stack to improve the morphologic evaluation of
923		urine cytology whole slide images for high-grade urothelial carcinoma: Results and review
924	~ 4	of a pilot study. <i>Cancer Cytopathology</i> 130 , 630–639 (2022).
925	74.	Allison, D. B. <i>et al.</i> Should the BK polyomavirus cytopathic effect be best classified as
926		atypical or benign in urine cytology specimens? <i>Cancer cytopathology</i> 124 , 436–442
927		(2016).
928	75.	Wu, Z. <i>et al.</i> Representing long-range context for graph neural networks with global
929		attention. Advances in Neural Information Processing Systems 34, 13266–13279 (2021).
930	76.	Levy, J. J., Salas, L. A., Christensen, B. C., Sriharan, A. & Vaickus, L. J. PathFlowAI: A
931		High-Throughput Workflow for Preprocessing, Deep Learning and Interpretation in Digital
932		Pathology. Pac Symp Biocomput 25, 403–414 (2020).
933	77.	Sundararajan, M., Taly, A. & Yan, Q. Axiomatic attribution for deep networks. in
934		Proceedings of the 34th International Conference on Machine Learning - Volume 70 3319–
935		3328 (JMLR.org, 2017).

- 78. Kokhlikyan, N. *et al.* Captum: A unified and generic model interpretability library for
 PyTorch. *arXiv:2009.07896 [cs, stat]* (2020).
- Falk, T. *et al.* U-Net: deep learning for cell counting, detection, and morphometry. *Nature methods* 16, 67–70 (2019).
- 80. Ronneberger, O., Fischer, P. & Brox, T. U-net: Convolutional networks for biomedical image segmentation. in *Medical Image Computing and Computer-Assisted Intervention– MICCAI 2015: 18th International Conference, Munich, Germany, October 5-9, 2015, Proceedings, Part III 18* 234–241 (Springer, 2015).
- 81. He, K., Zhang, X., Ren, S. & Sun, J. Deep Residual Learning for Image Recognition. in
 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR) 770–778
 (2016). doi:10.1109/CVPR.2016.90.
- 82. Koss, L. G., Deitch, D., Ramanathan, R. & Sherman, A. B. Diagnostic value of cytology of
 voided urine. *Acta cytologica* 29, 810–816 (1985).
- 83. Onur, I., Rosenthal, D. L. & VandenBussche, C. J. Benign-appearing urothelial tissue
 fragments in noninstrumented voided urine specimens are associated with low rates of
 urothelial neoplasia. *Cancer Cytopathology* 123, 180–185 (2015).
- 84. Thompson, C. G., Kim, R. S., Aloe, A. M. & Becker, B. J. Extracting the variance inflation
 factor and other multicollinearity diagnostics from typical regression results. *Basic and Applied Social Psychology* 39, 81–90 (2017).
- 85. Carvalho, C. M., Polson, N. G. & Scott, J. G. Handling Sparsity via the Horseshoe. in
 Artificial Intelligence and Statistics 73–80 (PMLR, 2009).
- 86. McKinley, T. J., Morters, M. & Wood, J. L. N. Bayesian Model Choice in Cumulative Link
 Ordinal Regression Models. *Bayesian Analysis* 10, 1–30 (2015).
- 87. Bender, R. & Grouven, U. Ordinal Logistic Regression in Medical Research. J R Coll
 960 Physicians Lond 31, 546–551 (1997).
- 961 88. OpenSeadragon. http://openseadragon.github.io/.
- 89. Wolfson, W. L. & Rosenthal, D. L. Cell clusters in urinary cytology. *Acta Cytol* 22, 138–141 (1978).
- 964 90. Mikou, P. *et al.* Evaluation of the Paris System in atypical urinary cytology. *Cytopathology* 29, 545–549 (2018).
- 966 91. Kurtycz, D. F. *et al.* Paris interobserver reproducibility study (PIRST). *Journal of the* 967 *American Society of Cytopathology* 7, 174–184 (2018).
- 968 92. Kurtycz, D. F. I., Sundling, K. E. & Barkan, G. A. The Paris system of Reporting Urinary
 969 Cytology: Strengths and opportunities. *Diagnostic Cytopathology* 48, 890–895 (2020).
- 970
 93. Bakkar, R. *et al.* Impact of the Paris system for reporting urine cytopathology on predictive values of the equivocal diagnostic categories and interobserver agreement. *Cytojournal* 16, (2019).
- 973 94. Hassan, M. *et al.* Impact of Implementing the Paris System for Reporting Urine Cytology in
 974 the Performance of Urine Cytology: A Correlative Study of 124 Cases. *American Journal*975 of Clinical Pathology 146, 384–390 (2016).
- 976 95. Pantanowitz, L. Automated pap tests. *Practical Informatics for Cytopathology* 147–155
 977 (2014).
- 978 96. Yamashita, S. *et al.* Urethral recurrence following neobladder in bladder cancer patients.
 979 *The Tohoku Journal of Experimental Medicine* **199**, 197–203 (2003).

- 980 97. Pierconti, F. *et al.* DNA methylation analysis in urinary samples: A useful method to
 981 predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder
 982 in the high-risk group. *Cancer Cytopathology* n/a,.
- 983 98. Shalata, A. T. *et al.* Predicting Recurrence of Non-Muscle-Invasive Bladder Cancer:
 984 Current Techniques and Future Trends. *Cancers* 14, 5019 (2022).
- 985 99. Soorojebally, Y. *et al.* Urinary biomarkers for bladder cancer diagnosis and NMIBC follow986 up: a systematic review. *World J Urol* 41, 345–359 (2023).
- 100. Lujan, G. *et al.* Dissecting the business case for adoption and implementation of digital
 pathology: a white paper from the digital pathology association. *Journal of Pathology Informatics* 12, 17 (2021).
- 101. Acs, B. & Rimm, D. L. Not just digital pathology, intelligent digital pathology. *JAMA oncology* 4, 403–404 (2018).
- 102. Jones-Hall, Y. Digital pathology in academia: Implementation and impact. *Lab Animal* 50, 229–231 (2021).
- 103. Olswang, L. B. & Prelock, P. A. Bridging the gap between research and practice:
 Implementation science. *Journal of Speech, Language, and Hearing Research* 58, S1818–
 S1826 (2015).
- 104. Li, R. C., Asch, S. M. & Shah, N. H. Developing a delivery science for artificial
 intelligence in healthcare. *npj Digit. Med.* 3, 1–3 (2020).
- 999 105. Char, D. S., Abràmoff, M. D. & Feudtner, C. Identifying ethical considerations for machine
 1000 learning healthcare applications. *The American Journal of Bioethics* 20, 7–17 (2020).
- 1001 106. Jackson, B. R. *et al.* The Ethics of Artificial Intelligence in Pathology and Laboratory
 1002 Medicine: Principles and Practice. *Acad Pathol* 8, (2021).
- 1003 107. Chauhan, C. & Gullapalli, R. R. Ethics of AI in pathology: current paradigms and emerging
 1004 issues. *The American journal of pathology* 191, 1673–1683 (2021).
- 1005 108. Baxi, V., Edwards, R., Montalto, M. & Saha, S. Digital pathology and artificial intelligence
 in translational medicine and clinical practice. *Modern Pathology* 35, 23–32 (2022).
- 1007 109. Niazi, M. K. K., Parwani, A. V. & Gurcan, M. N. Digital pathology and artificial
 1008 intelligence. *The Lancet Oncology* 20, e253–e261 (2019).
- 1009 110. Bouyssoux, A., Fezzani, R. & Olivo-Marin, J.-C. Cell Instance Segmentation Using Z 1010 Stacks in Digital Cytology. in 2022 IEEE 19th International Symposium on Biomedical
 1011 Imaging (ISBI) 1–4 (2022). doi:10.1109/ISBI52829.2022.9761495.
- 1012 111. Vaickus, L. J. & Tambouret, R. H. Young investigator challenge: The accuracy of the
 1013 nuclear-to-cytoplasmic ratio estimation among trained morphologists. *Cancer Cytopathol* 1014 123, 524–530 (2015).
- 1015 112. Butke, J. *et al.* End-to-end Multiple Instance Learning for Whole-Slide Cytopathology of
 1016 Urothelial Carcinoma. in *Proceedings of the MICCAI Workshop on Computational* 1017 *Pathology* 57–68 (PMLR, 2021).
- 1018 113. Lu, M. Y. *et al.* Data-efficient and weakly supervised computational pathology on whole1019 slide images. *Nature Biomedical Engineering* 1–16 (2021) doi:10.1038/s41551-020-006821020 w.
- 1021 114. Vargas, V. M., Gutiérrez, P. A. & Hervás-Martínez, C. Cumulative link models for deep ordinal classification. *Neurocomputing* 401, 48–58 (2020).
- 1023
- 1024





1028 Supplementary Figure 1: Important morphometric measures: A) Urothelial cells with high

- 1029 eccentricity; **B**) RBCs and crystals with high solidity; **C**) Leukocyte clusters with high convex
- 1030 area; D) Squamous cell with high convex area; E) Squamous cell with high solidity; F)
- 1031 Important morphometric features as determined using IntegratedGradients to accompany raw image features
- 1032 1033





1035 Supplementary Figure 2: Correlation Each Slide Feature and UC Atypia, ordered by

- 1036 predictiveness of each feature (spearman correlation / ordinal regression)
- 1037



1038 1039

- Supplementary Figure 3: Correlation Each Slide Feature and ABS, ordered by
- predictiveness of each feature for UC diagnostic category (spearman correlation / ordinal 1040 1041 regression)
- 1042
- 1043 Supplementary Table 1: Spearman correlation between imaging predictors, ABS and original
- 1044 UC Class

		ABS			Original Diagnosis			
Predictor	r	2.5% CI	97.5% CI	p-value	r	2.5% CI	97.5% CI	p-value
Overall number atypical cells	0.78	0.76	0.8	< 0.001	0.38	0.33	0.42	< 0.001
Overall number cells with high NC	0.53	0.48	0.56	< 0.001	0.27	0.22	0.32	< 0.001
Number of cells	0.63	0.6	0.67	< 0.001	0.29	0.24	0.34	< 0.001
Number of isolated atypical cells	0.73	0.7	0.75	< 0.001	0.37	0.32	0.42	< 0.001
Number of isolated cells with high NC	0.44	0.39	0.48	< 0.001	0.24	0.19	0.29	< 0.001
Number of atypical cells in clusters	0.75	0.73	0.78	< 0.001	0.36	0.31	0.41	< 0.001
Number of cells in clusters with high NC	0.57	0.53	0.61	< 0.001	0.3	0.25	0.35	< 0.001
Number of dense clusters	0.45	0.4	0.49	< 0.001	0.14	0.09	0.2	< 0.001
Number of clusters	0.53	0.49	0.57	< 0.001	0.21	0.15	0.26	< 0.001
Number of dense/atypical clusters	0.68	0.65	0.71	< 0.001	0.37	0.32	0.41	< 0.001
Number of atypical clusters	0.77	0.75	0.79	< 0.001	0.36	0.31	0.41	< 0.001
Age	0.21	0.16	0.26	< 0.001	0.11	0.06	0.16	< 0.001

1045

1046 Supplementary Table 2: Summary statistics (median, interquartile range) for each slide level

1047 feature and UC Class

	Overall	Negative	Atypical	Suspicious	Positive	р
Ν	1252	810	296	98	48	
Overall number	111.00 [24.00,	59.00 [16.00,	145.50 [46.75,	424.50 [151.50,	2029.50 [795.50,	< 0.001
atypical cells (median [IQR])	374.50]	240.50]	469.00]	1018.50]	4322.00]	
Overall number cells with high NC (median [IQR])	39.00 [6.00, 170.50]	24.00 [3.00, 120.75]	68.00 [10.00, 197.75]	96.00 [36.00, 279.25]	436.00 [160.50, 1995.75]	< 0.001
Number of cells (median [IQR])	2046.50 [590.25, 5856.25]	1480.00 [370.25, 4604.25]	2345.50 [933.50, 5629.50]	5734.00 [2165.50, 10514.00]	12178.00 [6810.00, 22094.75]	< 0.001

Number of isolated atypical cells (median [IQR])	57.50 [14.75, 212.25]	36.00 [9.00, 130.25]	94.50 [25.00, 252.75]	220.50 [84.50, 652.00]	1308.50 [565.25, 3127.50]	< 0.001
Number of isolated cells with high NC (median [IQR])	11.00 [1.00, 53.00]	7.00 [1.00, 38.00]	17.00 [3.00, 60.00]	28.00 [6.25, 89.75]	194.00 [51.00, 821.00]	< 0.001
Number of atypical cells in clusters (median [IQR])	24.00 [5.00, 110.25]	15.00 [3.00, 65.00]	36.00 [10.00, 123.75]	110.50 [34.25, 306.75]	631.50 [236.75, 1578.50]	< 0.001
Number of cells in clusters with high NC (median [IQR])	16.00 [2.00, 94.25]	9.00 [1.00, 53.00]	29.00 [5.00, 118.25]	59.00 [23.25, 122.00]	155.00 [92.25, 1159.25]	< 0.001
Number of dense clusters (median [IQR])	14.00 [4.00, 50.00]	11.00 [3.00, 45.75]	15.00 [4.75, 40.25]	22.50 [9.25, 59.00]	51.00 [16.50, 157.00]	< 0.001
Number of clusters (median [IQR])	1838.50 [674.75, 5228.50]	1455.50 [486.25, 4579.75]	1974.00 [807.50, 4744.25]	3255.00 [1574.25, 6367.25]	7917.50 [3695.50, 11501.00]	< 0.001
% clusters dense/atypical (median [IQR])	0.01 [0.00, 0.02]	0.01 [0.00, 0.01]	0.01 [0.01, 0.02]	0.02 [0.01, 0.03]	0.03 [0.02, 0.07]	< 0.001
Number of atypical clusters (median [IQR])	14.50 [3.00, 54.25]	9.00 [2.00, 36.00]	20.00 [6.00, 62.25]	57.50 [21.25, 180.75]	283.50 [105.50, 530.50]	<0.001
ABS (median [IQR])	0.05 [0.02, 0.15]	0.03 [0.01, 0.08]	0.07 [0.03, 0.18]	0.24 [0.15, 0.40]	0.42 [0.29, 0.57]	<0.001

1048



1049

1050 Supplementary Figure 4: Additional associations with specimen atypia: A) Boxplots

1051 depicting correlation between the percentage of urothelial cells with high atypia and UC Class;

1052 B) Scatterplot demonstrating correlation between slide level atypia via number of cells with high

- 1053 atypia and high NC ratio
- 1054
- 1055



1056 1057 1058

Supplementary Figure 5: Example of identifying malignant cells in atypical slide



1059

1060 Supplementary Figure 6: Example of identifying malignant cells in suspicious slide



1062 1063 Supplementary Figure 7: Example of identifying malignant cells in positive slide, only

1064 focusing on those with high atypia

1065



1066

1067 Supplementary Figure 8: Example of atypical cells identified using Autoparis-X web

application within demonstration on example atypical/positive slides: A) Isolated cell, B)

1069 Two cells with differing atypia; cell with larger red dot has higher atypia, C-D) Focusing on

specific cells identified using BorderDet in hard-to-separate clusters; E) Example table of

1071 malignant cells with reported atypia scores from suspicious case

- 1072
- 1073